Saturday, October 31, 2026

Align Technology Stock Impressive Rise Before The Weekend, Outperforms Market

ViaNews Editorial Team

December 15, 2023

Align Technology Stock  Impressive Rise Before The Weekend, Outperforms Market

(VIANEWS) - The NASDAQ ended the session with Align Technology rising 12.62% to $260.55 on Friday, following the last session's upward trend. NASDAQ rose 0.19% to $14,761.56, after five successive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Align Technology's last close was $231.36, 44.01% under its 52-week high of $413.20.

About Align Technology

Align Technology, Inc. designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, China, and internationally. It operates in two segments, Clear Aligner; and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go and Invisalign Go Plus; and non-case products that include retention products, Invisalign training, and adjusting tools used by dental professionals during the course of treatment. The Systems and Services segment offers iTero intraoral scanning system, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan, as well as subscription software, disposables, rentals, leases, and pay per scan services Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.

Earnings Per Share

As for profitability, Align Technology has a trailing twelve months EPS of $4.72.

PE Ratio

Align Technology has a trailing twelve months price to earnings ratio of 55.2. Meaning, the purchaser of the share is investing $55.2 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.68%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 7.8%, now sitting on 3.81B for the twelve trailing months.

Volatility

Align Technology's last week, last month's, and last quarter's current intraday variation average was 0.13%, 0.38%, and 2.14%.

Align Technology's highest amplitude of average volatility was 1.29% (last week), 1.31% (last month), and 2.14% (last quarter).

More news about Align Technology (ALGN).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com